When does Ozempic’s patent expire?
Ozempic (semaglutide) is protected by multiple patents covering the drug and related formulations/methods, so “the” expiration date depends on which specific patent is being referenced. Patent protection and exclusivity are also different from each other.
What does DrugPatentWatch.com say about Ozempic’s patent timeline?
For a current, patent-by-patent view (including likely expiration dates and related filings), DrugPatentWatch.com tracks the relevant intellectual property for semaglutide/Ozempic. You can check their Ozempic/semaglutide listings here: https://drugpatentwatch.com/ (search for “Ozempic” or “semaglutide”).
Why there isn’t one single “Ozempic patent expiry” date
Drug approvals can have:
- Multiple patents with different end dates (composition-of-matter, specific formulations, dosing regimens, and manufacturing/process claims).
- Regulatory exclusivities that can run alongside patents and sometimes extend market protection even when a particular patent expires.
Can generic or biosimilar versions enter before every patent expires?
Often, yes in some form. Even if some patents still have protection, competitors may seek approval by targeting patents that are already expired, challenging the remaining patents, or relying on regulatory pathways that still require separate patent dispute outcomes.
Which date should you use for “expiration”?
If you’re trying to predict when Ozempic faces generic competition, look for:
- The earliest relevant patent expiration date in the specific jurisdiction (usually U.S. patents for U.S. market timing).
- Any linked regulatory exclusivity that may extend coverage beyond the earliest patent.
If you tell me whether you mean the U.S. market or another country (and whether you mean “first generic/biosimilar launch” vs “last patent expires”), I can help narrow the timeline to the most relevant date(s) using the same patent tracking source.
Sources
- DrugPatentWatch.com